NYX‐458 Improves Cognitive Performance in a Primate Parkinson's Disease Model

BACKGROUND NYX‐458 is a N‐methyl‐ d ‐aspartate receptor (NMDAR) modulator that enhances synaptic plasticity. Dopaminergic cell loss in Parkinson's disease (PD) leads to NMDAR dysregulation in the cortico‐striato‐pallidal‐thalmo‐cortical network and altered plasticity in brain regions important to cognitive function. We hypothesize that targeting the NMDAR may be an efficacious approach to treating cognitive impairment in PD. OBJECTIVES NYX‐458...